Should You Buy This High-Yielding Big Pharma Stock?
High inflation and rising interest rates often adversely impact the performance of growth stocks. Investors can look no further than the tech-oriented Nasdaq Composite's 26% year-to-date drop as evidence of this claim.
On the other hand, income stocks have performed very well so far this year. Shares of Swiss pharma stock Novartis (NYSE: NVS) have remained flat year to date. But should yield-focused investors buy the stock? Let's take a look at Novartis' fundamentals and valuation to find out.
Image source: Getty Images.
Source Fool.com
